Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
In this edition of Clinical Quandaries Eder A. Arango Bravo, MD, and colleagues present a 63 year old woman who has cervical cancer with kidney failure and additional comorbidities.
Those immunized between the ages of 12 and 13 in England experienced a significant estimated reduction in cervical cancer and grade 3 cervical intraepithelial neoplasia incidence rates compared with unvaccinated women.
Patients with recurrent or metastatic cervical cancer treated with cemiplimab experienced an improved overall survival, progression-free survival, and overall response rate, leading to priority review from the FDA.
Tisotumab vedotin may now be used to treat patients with recurrent or metastatic cervical cancer after the FDA's decision to grant the agent an accelerated approval.
Results of a single-arm study indicate that patients with previously treated metastatic cervical cancer may derive benefit from treatment with balstilimab plus zalifrelimab.
Examination of tisotumab vedotin plus key standard-of-care therapeutics shows promise for the treatment of cervical cancer in the frontline setting and beyond.
Patients with cervical cancer receiving pembrolizumab plus chemotherapy with or without bevacizumab in the frontline setting had improvement in overall survival, potentially representing a new standard of care regimen.
The World Health Organization has published new recommendations to aid in the global prevention of cervical cancer through more accessible screenings and treatments.
Merck’s press release announced positive data from the KEYNOTE-826 trial investigating pembrolizumab plus chemotherapy with or without bevacizumab for patients with cervical cancer.